azenosertib   Click here for help

GtoPdb Ligand ID: 11731

Synonyms: compound 16 [PMID: 34423975] | ZN-c3 | ZNc3
PDB Ligand
Compound class: Synthetic organic
Comment: ZN-c3 is a potent inhibitor of WEE1 G2 checkpoint kinase (WEE1) that was developed for anti-cancer potential [1]. Inhibition of Wee1 in cancer cells that rely on G2/M checkpoint regulation for survival, disrupts G2/M cell cycle arrest which leads to premature entry into mitosis, replication stress and ultimately cell death. The chemical structure of ZN-c3 matches that for the INN 'azenosertib' which was published in the WHO's proposed INN list 127 on 21 July 2022.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 103.82
Molecular weight 526.28
XLogP 2.93
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES C=CCn1c(=O)c2c(n1c1ccc3c(n1)[C@@](O)(CC)CC3)nc(nc2)Nc1ccc(cc1)N1CCN(CC1)C
Isomeric SMILES O=c1n(CC=C)n(c2ccc3CC[C@@](CC)(O)c3n2)c2nc(Nc3ccc(N4CCN(C)CC4)cc3)ncc12
InChI InChI=1S/C29H34N8O2/c1-4-14-36-27(38)23-19-30-28(31-21-7-9-22(10-8-21)35-17-15-34(3)16-18-35)33-26(23)37(36)24-11-6-20-12-13-29(39,5-2)25(20)32-24/h4,6-11,19,39H,1,5,12-18H2,2-3H3,(H,30,31,33)/t29-/m1/s1
InChI Key OXTSYWDBUVRXFF-GDLZYMKVSA-N
No information available.
Summary of Clinical Use Click here for help
ZN-c3 has progressed to clinical evaluations to determine efficacy against a number of solid tumour types.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04158336 A Study of ZN-c3 in Participants With Solid Tumors Phase 1 Interventional K-Group Beta
NCT04814108 A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma Phase 2 Interventional K-Group Beta
NCT04833582 A Study of ZN-c3 in Combination With Gemcitabine in Subjects With Osteosarcoma Phase 1/Phase 2 Interventional K-Group Beta